EQS-News: Protalix BioTherapeutics Inc.: Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment

EQS-News: Protalix BioTherapeautics Inc. Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment 30.11.2022 / 21:00 CET/CEST The issuer is solely responsible for the content

Related Keywords

Italy ,United States ,Israel ,Brazil ,Israeli ,Dror Bashan ,Chiesi Farmaceutici ,Giacomo Chiesi ,Chuck Padala ,Protalix Biotherapeutics Inc ,Company Website ,Drug Administration ,Nasdaq ,Sangamo Therapeutics Inc ,Distribution Services ,Protalix Biotherapeautics Inc ,Pfizer Inc ,Protalix Biotherapeutics ,Chiesi Group ,News Service ,Avrobio Inc ,Freeline Therapeutics Holdings ,Chiesi Resubmit ,For Rare Disease Treatment ,Chiesi Global Rare Diseases ,Biologics License Application ,Chief Executive ,Sangamo Therapeutics ,Corporate News ,Regulatory Announcements ,News ,Protalix ,Iotherapeutics ,Thiesi ,Resubmit ,Application ,Mare ,Disease ,Treatment ,